Role of omega-3 polyunsaturated fatty acids in gestational diabetes, maternal and fetal insights: current use and future directions

Elshani, Brikene; Kotori, Vjosa Mulliqi; Daci, Armond

doi:10.1080/14767058.2019.1593361

Cited by 14 publications

(9 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The consumption of saturated fat should be limited in favor of the consumption of the polyunsaturated fatty acids (PUFA) n-3 (linolenic acid) and n-6 (linoleic acid), which are the most important fatty acids for fetal growth and development. A total intake of n-3 in the amount of 2.7 g/day is considered safe during pregnancy [ 77 ], while additional fish oil supplementation gives inconclusive results [ 83 ]. The recommended weight gain in pregnancy amounts to on average 8–12 kg, depending on the initial body weight ( Table 3 ) [ 78 ].…”

Section: Resultsmentioning

confidence: 99%

Gestational Diabetes Mellitus—Recent Literature Review

Modzelewski

Stefanowicz-Rutkowska

Matuszewski

et al. 2022

JCM

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM), which is defined as a state of hyperglycemia that is first recognized during pregnancy, is currently the most common medical complication in pregnancy. GDM affects approximately 15% of pregnancies worldwide, accounting for approximately 18 million births annually. Mothers with GDM are at risk of developing gestational hypertension, pre-eclampsia and termination of pregnancy via Caesarean section. In addition, GDM increases the risk of complications, including cardiovascular disease, obesity and impaired carbohydrate metabolism, leading to the development of type 2 diabetes (T2DM) in both the mother and infant. The increase in the incidence of GDM also leads to a significant economic burden and deserves greater attention and awareness. A deeper understanding of the risk factors and pathogenesis becomes a necessity, with particular emphasis on the influence of SARS-CoV-2 and diagnostics, as well as an effective treatment, which may reduce perinatal and metabolic complications. The primary treatments for GDM are diet and increased exercise. Insulin, glibenclamide and metformin can be used to intensify the treatment. This paper provides an overview of the latest reports on the epidemiology, pathogenesis, diagnosis and treatment of GDM based on the literature.

show abstract

Section: Resultsmentioning

confidence: 99%

Gestational Diabetes Mellitus—Recent Literature Review

Modzelewski

Stefanowicz-Rutkowska

Matuszewski

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Omega-3 PUFAs are beneficial in the regulation of maternal and fetal metabolic function, inflammation, immunity, macrosomia, oxidative stress, pre-eclampsia, FGR, preterm birth, offspring metabolic function, and neurodevelopment. 17 PUFAs have antioxidant activity, thus dietary supplementation of these substances during pregnancy has the potential to prevent or control placental disorders and promote fetal growth. 18 In our study, maternal FAs levels showed different behaviors in pregnant women with FGR and AGA fetuses.…”

Section: Discussionmentioning

confidence: 99%

Maternal Blood Fatty Acid Levels in Fetal Growth Restriction

Grohmann

Marçal

Corazza

et al. 2023

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Objective: To assess the maternal blood levels of fatty acids (FAs) in pregnancies with fetal growth restriction (FGR). Methods: This prospective cross-sectional study included pregnant women with gestational age between 26 and 37 + 6 weeks with FGR and appropriate for gestational age (AGA) fetuses. The levels of saturated, trans, monounsaturated, and polyunsaturated FAs were measured using centrifugation and liquid chromatography. The Student's t-test, Mann–Whitney test, and general linear model, with gestational age and maternal weight as covariants, were used to compare FA levels and the FGR and AGA groups. The Chi-square was used to evaluate the association between groups and studied variables. Results: Maternal blood sample was collected from 64 pregnant women, being 24 FGR and 40 AGA. A weak positive correlation was found between the palmitoleic acid level and maternal weight (r = 0.285, p = 0.036). A weak negative correlation was found between the gamma-linoleic acid level and gestational age (r = − 0.277, p = 0.026). The median of the elaidic acid level (2.3 vs. 4.7 ng/ml, p = 0.045) and gamma-linoleic acid (6.3 vs. 6.6 ng/ml, p = 0.024) was significantly lower in the FGR than the AGA group. The palmitoleic acid level was significantly higher in the FGR than AGA group (50.5 vs. 47.6 ng/ml, p = 0.033). Conclusion: Pregnant women with FGR had lower elaidic acid and gamma-linoleic acid levels and higher palmitoleic acid levels than AGA fetuses.

show abstract

“…The FFAR4 expression may be influenced by polymorphisms, so, they can influence the therapeutic consequences of Omega-3 PUFA administration. Supplementation with Omega-6 PUFAs indicated an increase in the AA levels in GDM which is associated with improved insulin sensitivity, glucose levels, and reducing obesity [ 40 ]. The beneficial effect of ω-3 and ω-6 FAs in GDM patients and their offspring have been reported while their role in GDM prevention is unclear.…”

Section: Discussionmentioning

confidence: 99%

Association of circulating omega 3, 6 and 9 fatty acids with gestational diabetes mellitus: a systematic review

et al. 2021

View full text Add to dashboard Cite

Background Gestational diabetes mellitus (GDM) is associated with increased risks of disease for mother and child during pregnancy and after that. Early diagnosis of GDM would promote both maternal and fetal health. Metabolomics can simplify and develop our understanding of the etiology, manifestation, or pathophysiology of the disease. This systematic review investigates the association of circulating omega 3, 6, and 9 fatty acids with GDM. Methods We conducted a systematic search of PubMed, Scopus, Web of Science, and EMBASE databases up to May 8, 2020, using the key term combinations of all types of omega fatty acids with gestational diabetes mellitus. Additional articles were identified through searching the reference lists of included studies. Results This systematic review included 15 articles. Five were cohort studies, four included nested case-control studies and four were case-control studies. The results of this study demonstrate an increasing trend in the amount of oleic acid and palmitoleic acid in the second trimester and an increase in decosahexanoic acid in the third trimester of GDM mothers. The changes in other fatty acids of interest are either not significant or if significant, their results are inconsistent with the other existing articles. Conclusions Omega fatty acids, as potential biomarkers, are considered to be associated with GDM risk and thus provide useful information regarding the prevention and early diagnosis of GDM. Moreover, existing metabolomic studies on GDM are shown to provide conflicting results about metabolite profile characteristics. This systematic review was registered at PROSPERO (www.crd.york.ac.uk/PROSPERO) as CRD42020196122.

show abstract

Role of omega-3 polyunsaturated fatty acids in gestational diabetes, maternal and fetal insights: current use and future directions

Cited by 14 publications

References 93 publications

Gestational Diabetes Mellitus—Recent Literature Review

Gestational Diabetes Mellitus—Recent Literature Review

Maternal Blood Fatty Acid Levels in Fetal Growth Restriction

Association of circulating omega 3, 6 and 9 fatty acids with gestational diabetes mellitus: a systematic review

Contact Info

Product

Resources

About